Hemoglobin–Albumin Cluster Incorporating a Pt Nanoparticle: Artificial O2 Carrier with Antioxidant Activities

Hitomi Hosaka1, Risa Haruki1, Kana Yamada1, Christoph Böttcher2, Teruyuki Komatsu1*

1 Department of Applied Chemistry, Faculty of Science and Engineering, Chuo University Tokyo, Japan, 2 Research Center of Electron Microscopy, Institute of Chemistry and Biochemistry Freie Universität Berlin, Berlin, Germany

Abstract

A covalent core–shell structured protein cluster composed of hemoglobin (Hb) at the center and human serum albumins (HSA) at the periphery, Hb-HSAm, is an artificial O2 carrier that can function as a red blood cell substitute. Here we described the preparation of a novel Hb-HSA3 cluster with antioxidant activities and its O2 complex stable in aqueous H2O2 solution. We used an approach of incorporating a Pt nanoparticle (PtNP) into the exterior HSA unit of the cluster. A citrate reduced PtNP (1.8 nm diameter) was bound tightly within the cleft of free HSA with a binding constant (K) of 1.1×107 M−1, generating a stable HSA-PtNP complex. This platinated protein showed high catalytic activities for dismutations of superoxide radical anions (O2−) and hydrogen peroxide (H2O2), i.e., superoxide dismutase and catalase activities. Also, Hb-HSA3 captured PtNP into the external albumin unit (K=1.1×107 M−1), yielding an Hb-HSA3(PtNP) cluster. The association of PtNP caused no alteration of the protein surface net charge and O2 binding affinity. The peripheral HSA-PtNP shell prevents oxidation of the core Hb, which enables the formation of an extremely stable O2 complex, even in H2O2 solution.

Introduction

Hemoglobin (Hb)-based O2 carriers (HBOCs) have been studied extensively as a substitute for red blood cells (RBCs) in transfusion medicine and as O2 therapeutic reagents [1–5]. Nevertheless, none satisfies all requirements for use in clinical situations [6,7]. A common side-effect is mild hypertension resulting from nitric oxide (NO) depletion by Hb diffused into the extravascular space [8,9]. Actually, NO is an endothelial-derived relaxing factor. Moreover, HBOCs show faster autoxidation of Hb to the ferric heme form (metHb) than the native Hb shows [10–12]. Autoxidation of Hb produces a superoxide radical anion (O2−), which is disproportionated to hydrogen peroxide (H2O2) [13]. These reactive oxygen species (ROS) promote the oxidation of Hb. In RBC, antioxidant systems include superoxide dismutase (SOD) and catalase, which catalytically scavenge O2− and H2O2, and thereby protect the Hb function. In ischemia-reperfusion when the ischemic tissue is reperfused with O2, xanthine oxidase converts xanthine and hypoxanthine into O2− [14–16]. Overproduction of O2− and subsequently H2O2 causes not only tissue injury, but also further oxidation of Hb. Consequently, in clinical situations involving ischemia-reperfusion, HBOC with antioxidant activity is expected to be tremendously useful. Chang et al. first synthesized polyHb-SOD-catalase conjugate and demonstrated the reduction of the autoxidation rate of Hb [17]. Kluger et al. reported that the metHb formation was inhibited in structurally defined Hb-SOD dimer [18]. Silaghi-Dumitrescu et al. prepared Hb copolymer with ruberythrin, non heme iron enzyme [19]. These Hb-[antioxidant enzyme] conjugates displayed both O2 carrying and antioxidant properties. However, a specific enzyme is necessary to scavenging the iodized ROS, and it denatures gradually.

More recently, we synthesized a covalent core–shell structured protein cluster comprising Hb at the center and human serum albumins (HSA) at the periphery, Hb-HSAm (m = 2, 3, 4), which acts as a unique HBOC (Figure 1) [20]. Since HSA contains only one cysteinyl thiol at position 34, we exploited a heterobifunctional crosslinker, N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), as a connector between the Cys-34 residue of HSA and the surface lysyl carboxylate (SMCC), yielding an Hb-HSA3(PtNP) cluster. The association of PtNP caused no alteration of the protein surface net charge and O2 binding affinity. The peripheral HSA-PtNP shell prevents oxidation of the core Hb, which enables the formation of an extremely stable O2 complex, even in H2O2 solution.

Citation: Hosaka H, Haruki R, Yamada K, Böttcher C, Komatsu T (2014) Hemoglobin–Albumin Cluster Incorporating a Pt Nanoparticle: Artificial O2 Carrier with Antioxidant Activities. PLoS ONE 9(10): e110541. doi:10.1371/journal.pone.0110541

Editor: Eugene A. Perymyakov, Russian Academy of Sciences, Institute for Biological Instrumentation, Russian Federation

Received July 17, 2014; Accepted September 17, 2014; Published October 13, 2014

Copyright: © 2014 Hosaka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.

Funding: This work was supported by a Grant-in-Aid for Scientific Research on Innovative Area (“Coordination Programming” Area 2107, No. 21108013) from MEXT (Ministry of Education, Culture, Sports, Science and Technology) Japan, Chuo University Grant for Special Research, and Joint Research Grant from the Institute of Science and Engineering, Chuo University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: komatsu@kc.chuo-u.ac.jp

PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110541
long-term circulation without extravasation. Moreover, it might not elicit an unfavorable increase in blood pressure.

If one were able to confer antioxidant properties to the external HSA unit of Hb-HSAm, then this construct would become a promising O2 carrier with high resistance towards oxidation reactions. In this context, we chose Pt nanoparticle (PtNP) as a potential candidate. PtNPs have been widely investigated for a variety of applications, such as fine chemical synthesis, fuel cell fabrications, and biomedical treatments. It was reported that PtNP is an extremely effective catalysis for both O2\textsuperscript{2−} and H2O2 dismutations (Figure 1) [22–24]. (i) The high ROS scavenging activities of PtNP depend on greater surface area per mass relative to large particle [22,23]. (ii) Almost no cytotoxicity was observed even after adherent cells were exposed to PtNPs [23]. We have found that small PtNP (1.8 nm diameter) is incorporated into HSA, and the obtained HSA-PtNP complex showed SOD and catalase activities with high efficiency. The Hb-HSA\textsubscript{3} also possesses the capability of binding PtNP into the exterior HSA shell. The resultant Hb-HSA\textsubscript{3}(PtNP) cluster forms a very stable O2 complex, even in aqueous H2O2 solution (Figure 1). This artificial O2 carrier, having triple functionalities (O2 transport, O2\textsuperscript{2−} dismutation, H2O2 dismutation) might be useful in clinical conditions with ischemia-reperfusion. The Hb-HSA\textsubscript{3}(PtNP) cluster would deliver O2 to the ischemic tissue, and simultaneously protect Hb and tissues from damaging effects of reperfusion injury.

**Materials and Methods**

**Materials and apparatus**

Human serum albumin (HSA) was purchased from Japan Blood Products Organization. Pure bovine Hb was purified from bovine blood purchased from Tokyo Shibaura Zouki Co., Ltd. [20]. Hydrogen hexachloroplatinate(IV) hexahydrate (H2PtCl6\textsubscript{6}H2O), xanthine, and catalase (from bovine liver) were purchased from Wako Pure Chemical Industries Ltd. Ferricytochrome c (Cyt. c, from bovine heart) was purchased from Sigma-Aldrich Co. Xanthine oxidase (XOD, from butter milk) was purchased from Oriental Yeast Co., Ltd. Mn(III)-terakis(N-methylpyridinium) porphyrin (Mn-TMPyP) was purchased from Frontier Scientific Corp. Other chemicals of special grades were used without further purification. The water was deionized (18.2 M\textsuperscript{2} cm) using water purification systems (Elix UV and Milli Q Reference; Millipore Corp.). Isoelectric focusing (IEF) was performed using an electrophoresis power supply (EPS 601; GE Healthcare UK Ltd.) with an IEF gel (Novex pH 3–10; Invitrogen Corp.). The protein marker used was an IEF calibration kit Broad pl (pH 3–10; GE Healthcare UK Ltd.).

**Synthesis of PtNP**

The citrate-reduced PtNP was prepared as described in a report of a study by Bond et al. [25]. To the refluxed aqueous H2PtCl6\textsubscript{6}H2O solution (271 \mu M, 85.5 mL), 1 wt% trisodium citrate dihydrate in water (4.5 mL) was added and then refluxed continuously for 1 h with stirring. The solution changed to dark brown. After cooling slowly to 25\textdegree C, the obtained PtNP solution was washed with water using an ultrafilter (Q0100, 10 kDa).

**Figure 1. Schematic illustrations of Hb-HSA\textsubscript{3}(PtNP) cluster.** The Cys-34 of HSA and the surface Lys group of Hb were connected covalently with a crosslinking agent (SMCC). A PtNP was bound within the cleft of the exterior HSA unit and performed SOD and catalase activities. doi:10.1371/journal.pone.0110541.g001
MWCO; Advantec Toyo Kaisha Ltd.) in an UHP-76K ultraholder. Finally, the medium was concentrated up to 50 μM as PtNP using the UHP-76K ultraholder. The resultant PtNP colloid solution was stored in a refrigerator at 4°C.

Preparation of Hb-HSA

The Hb-HSA₃ cluster was prepared according to our previously reported procedure with some modifications [20]. Typically, a DMSO solution of heterobifunctional crosslinker, N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC; Tokyo Chemical Industry Co., Ltd.) (20 mM, 4 mL) was added dropwise into phosphate buffered saline (PBS) solution (pH 7.4) of carbonyl Hb (0.1 mM, 40 mL), and the mixture was stirred for 3 h in the dark at 4°C. After removing unreacted crosslinker by gel filtration chromatography (GFC) with a Sephadex G25 (superfine) column, the obtained SMCC-bound Hb (maleimide activated Hb) was concentrated to 40 mL ([Hb] = 0.1 mM) using a centrifugal concentrator (Vivaspin 20 ultrafilter, 10 kDa MWCO; GE Healthcare UK Ltd.). Then this solution was added slowly into the PBS solution of HSA (1 mM, 40 mL) with subsequent stirring under dark conditions for 14 h at 4°C. A part of reaction mixture was applied to size-exclusion chromatography (SEC) on an HPLC system (LaChrom Elite; Hitachi High-Technologies Corp.) with a Shodex Protein KW-803 column (Showa Denko K.K.) using phosphate buffer (PB, pH 7.4, 50 mM) as the mobile phase. The elution curve exhibited new multiple peaks at the high molecular weight region. The three major components were identified as Hb-HSA₄ heteropentamer (minor), Hb-HSA₃ heterotetramer, and Hb-HSA₂ heterotrimer [20]. Then the resultant solution was subjected to GFC with a Superdex 200 pg in XK50/60 column (GE Healthcare UK Ltd.) using PBS (pH 7.4) as the running buffer. We collected all major fractions before the HSA peak. The unreacted free HSA was excluded completely. By Hb and total protein assays [20], the average HSA/Hb ratio of the harvested Hb-HSA₃ cluster was found to be 2.8–3.2, which is indicated as Hb-HSA₃. Finally, the obtained Hb-HSA₃ solution was condensed ([Hb] = 5 g/dL) using a Vivaspin 20 ultrafilter (30 kDa MWCO) and stored in a refrigerator at 4°C.

Figure 2. Crystal structure of HSA (PDB 1E78, ref. 31) and the PtNP binding site. (A) HSA structure involving the positions of drug site 1 (subdomain IIA, dark green), drug site 2 (subdomain IIIA, dark blue), Cys-34, and Trp-214. Cys-34 and Trp-214 are depicted in space-filling representation. The upper image and lower images respectively show the “front side” and “back side”. (B) Surface electrostatic potential representations of HSA in the same orientations illustrated in (A). Blue and red respectively represent positive charge and negative charge density. Possible binding site of PtNP in the positively charged cleft between subdomain IIA and IIIA is indicated by a yellow circle. These images were produced based on crystal structure coordinates using PyMOL (Schrodinger K.K., CA, USA).

doi:10.1371/journal.pone.0110541.g002
CD measurements

Circular dichroism (CD) spectra were obtained using a spectropolarimeter (J-820; Jasco Corp.). The sample concentration was 0.2 mM in PBS. Quartz cuvettes with 10-mm thickness were used for measurements of 200–250 nm.

Preparation of HSA-PtNP complex and Hb-HSA₃(PtNP) cluster

The medium of PtNP solution was exchanged to PBS (pH 7.4) using a Vivaspin 20 ultrafilter (10 kDa MWCO). A PBS solution of HSA (0.51 mM, 0.1 mL) was added slowly to the PtNP solution (10.2 μM, 5 mL, PBS), and the mixture was incubated for 1 h with gentle stirring in the dark at 25°C, yielding HSA-PtNP complex (PtNP/HSA = 1/1). Similarly, the Hb-HSA₃ solution (0.51 mM, 0.2 mL, PBS) was added to the PtNP solution (10.2 μM, 10 mL, PBS). Then the mixture was incubated for 1 h with gentle stirring in the dark at 25°C, affording Hb-HSA₃(PtNP) cluster (PtNP/Hb-HSA₃ = 1/1).

Determination of binding constants of PtNP for HSA and cluster

Binding constants ($K$) of PtNP for HSA and Hb-HSA₃ cluster were determined using fluorescence quenching measurements of albumin by PtNP titration according to the literature [26]. Fluorescence of the HSA or Hb-HSA₃ ([HSA unit] = 10 μM) ($E_{ex}$: 340 nm) solution (PBS, pH 7.4) was quenched upon binding of PtNP (0–0.3 μM). The plots of $\log(F_0 - F)/F$ vs. $\log[PtNP]$ were produced from the data to obtain the $K$ values and binding number.

Table 1. $O_2^{•−}$ scavenging activity (IC₅₀) and $H_2O_2$ scavenging activity (T₅₀) of HSA-PtNP complex at 25°C.

| Enzyme mimics | IC₅₀ (μM)ᵃ | T₅₀ (min)ᵇ |
|---------------|-------------|------------|
| HSA           | N.D.        | N.D.       |
| PtNP          | 0.12        | 6          |
| HSA-PtNP      | 0.16        | 19         |
| Mn-TMPyP      | 0.8⁷        | N.D.       |
| Cu,Zn-SOD     | 0.03⁸       | –          |
| Catalase      | –           | ≈0.1       |

ᵃIn PB solution (pH 7.8, 50 mM).
ᵇIn PBS solution (pH 7.4), [H₂O₂] = 0.1 mM.
⁷Ref. 29.
⁸Ref. 33. In PB solution (pH 7.8, 45 mM).

doi:10.1371/journal.pone.0110541.t001

Figure 3. TEM images of HSA-PtNP complexes. The sample was negatively stained with 1% uranyl acetate. doi:10.1371/journal.pone.0110541.g003

Figure 4. Time course of residual $H_2O_2$ percentage in 0.1 mM $H_2O_2$ solution with HSA-PtNP complex. [Sample] = 1 μM at 25°C. doi:10.1371/journal.pone.0110541.g004
Droplets of HSA-PtNP ([protein] = 0.35 mg/mL) were applied to amorphous carbon film covered 200-mesh grids (Quantifoil R1/4 with a hole diameter of approximately 1 μm; Quantifoil Micro Tools GmbH, Jena, Germany), which had been hydrophilized before use by plasma treatment (8 W, 60 s) in a Baltec Med 020 device (Leica Microsystems). After the supernatant fluid was blotted with a filter paper, an aqueous uranyl acetate (1 w/v %) was applied for another 45 s and the grids were eventually left to air-dry after blotting. Then the grids were transferred into a transmission electron microscope (Tecnai F20 microscope equipped with field emission gun operated at a 160 kV accelerating voltage; FEI Co.). Images were recorded using a CCD camera (Eagle 4k-CCD device; FEI Co.) operated at a binning factor of 2 (2,048×2,048 pixel).

**O$_2^-$ scavenging activity (xanthine–XOD–Cyt. c assay)**

$O_2^-$ scavenging activity (SOD activity) of the HSA-PtNP complex was determined using the Cyt. c reduction technique, in which $O_2^-$ was produced in situ by a xanthine–XOD reaction [27,28]. The experiments were performed according to our previously reported procedure [29]. To the PB solution (pH 7.8, 50 mM, 3.0 mL) containing Cyt. c (10 μM), xanthine (50 μM), and catalase (500 U/mL) in a 10-mm path length optical quartz cuvette, an amount of XOD sufficient to give an initial rate of $\Delta A_{550} = 0.025 \text{ min}^{-1}$ (without HSA-PtNP complex) (approximately 2.0 mU/mL) was injected at 25°C. After the addition of XOD, increases in the absorption at 550 nm based on the reduced-form Cyt. c was monitored at 25°C. From the absorbance increase, the initial rate constant ($v_i$) was determined at various concentration of HSA-PtNP complex. The IC$_{50}$ value is defined as the 50% inhibition concentration of Cyt. c reduction. The same experiments were also conducted for PtNP and HSA.

**H$_2$O$_2$ scavenging activity (quantitative peroxide assay)**

H$_2$O$_2$ scavenging activity (catalase activity) of the HSA-PtNP complex was evaluated by measuring the concentration of residual H$_2$O$_2$ using the Pierce Quantitative Peroxide Assay Kits (Thermo Fisher Scientific Inc.). The HSA-PtNP solution (50 μM, 41 μL) was added to the aqueous solution of H$_2$O$_2$ (102 μM, 2.0 mL) in a vial bottle. Then the mixture was incubated with gentle stirring at 25°C. The 50 μL sample was pipetted out regularly from the reaction mixture and HSA-PtNP was removed using a centrifugal
Table 2. Visible absorption spectral data of Hb-HSA<sub>3</sub> and Hb-HSA<sub>3</sub>(PtNP) clusters in PBS solution (pH 7.4) at 25 °C.

| Hemoproteins       | deoxy   | oxy     | carbonyl |
|--------------------|---------|---------|----------|
| Hb-HSA<sub>3</sub> | 430, 556| 413, 541, 577| 420, 538, 569 |
| Hb-HSA<sub>3</sub>(PtNP) | 430, 554| 413, 541, 576| 419, 536, 568 |
| Hb<sup>a</sup> | 430, 555| 414, 541, 577| 420, 538, 569 |
| Hb<sup>b</sup> | 430, 555| 415, 541, 577| 419, 540, 569 |

*From ref. 20.

<sup>a</sup>HbA (human adult Hb), from ref. 36.

<sup>b</sup>From ref. 20.

O<sub>2</sub> complex stability

The O<sub>2</sub> complex stability of the Hb-HSA<sub>3</sub> cluster was evaluated using the first-order autoxidation rate constant (k<sub>ox</sub>) of the central Hb. The PBS solution (pH 7.4) of oxyHb-HSA<sub>3</sub> cluster ([Hb] = 10 μM, 2 mL) was put into a 10-mm-path length quartz cuvette. The top of the cuvette was sealed with a gas permeation film (AeraSeal Film MA710; Gel Co.), which allows air exchange and which prevents water evaporation. The absorption intensity at 630 nm (A<sub>t</sub>) based on methHb formation was measured under aerobic conditions at 37 °C. After the measurement, the entirely oxidized metHb-HSA<sub>3</sub> cluster was prepared by addition of slightly excess K<sub>3</sub>[Fe(CN)<sub>3</sub>]<sup>3-</sup>, and its absorption intensity (A<sub>100</sub>) was observed. From the absorbance increase, the k<sub>ox</sub> value was ascertained using nonlinear least-squares curve fitting techniques. The same experiments were conducted for native Hb and Hb-HSA<sub>3</sub>(PtNP) cluster.

The O<sub>2</sub> complex stability of the cluster in 20 μM H<sub>2</sub>O<sub>2</sub> solution was evaluated by the time course of metHb formation level because the mechanism of the Hb oxidation was complicated. To the PBS solution (pH 7.4) of oxyHb-HSA<sub>3</sub> cluster ([Hb] = 10 μM, 2 mL) in a 10-mm-path length quartz cuvette, aqueous H<sub>2</sub>O<sub>2</sub> (2 mM, 20 μL) was added, and the absorption intensity at 630 nm (A<sub>t</sub>) was measured under aerobic conditions with gentle stirring for 180 min at 25 °C. The top of the cuvette was sealed with a gas permeation film. After the measurement, a slightly excess K<sub>3</sub>[Fe(CN)<sub>3</sub>]<sup>3-</sup> was added to determine the absorption intensity of the entirely oxidized metHb form (A<sub>100</sub>). From the absorbance increase, the metHb level [A<sub>t</sub>−A<sub>0</sub>]/[A<sub>100</sub>−A<sub>0</sub>]×100 (%) (A<sub>100</sub>: absorption intensity at 630 nm before H<sub>2</sub>O<sub>2</sub> injection) was ascertained. The same experiments were carried out for native Hb, Hb-HSA<sub>3</sub>(PtNP) cluster, and simple mixture of Hb/HSA-PtNP/HSA (1/1/2, molar ratio).

Results and Discussion

Synthesis and structure of HSA–PtNP complex

Enzymatic activities of PtNP have attracted considerable attention because of their potential applications for medical use [22–24]. Shirahata et al. reported high O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> dismutation activities of PtNPs and the highest enzyme reactivity at a particle size of about 2.0 nm [23]. In the circulatory system, the small PtNP (ca. 2 nm diameter) might be captured by HSA. However, the enzymatic properties of such postulated HSA-PtNP complex have not been reported in the relevant literature. We have now prepared the HSA-PtNP complex and have examined its O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> dismutation activities.

HSA is a heart-shaped monomeric protein (66.5 kDa) consisting of three homologous domains (I–III), each of which contains two subdomains: A and B (Figure 2A) [30,31]. Many water insoluble
metabolites (fatty acids, bilirubin, thyroxin, etc.) and commonly used drugs (warfarin, diazepam, ibuprofen, etc.) bind to the principal ligand binding sites in subdomain IIA and IIIA of HSA: so-called drug sites 1 and 2 [32]. To embed a PtNP into this protein interior, we prepared citrate-reduced PtNP with a diameter of 1.5–2.0 nm [25]. TEM images clearly showed the formation of uniform PtNPs with diameter \(d\) of 1.8 nm. The PtNP concentration was calculated as 1.25 \(\mu\)M based on the Pt\(^{2+}\) concentration and particle size. The resultant aqueous PtNP solution was concentrated up to 50 \(\mu\)M using an ultrafiltration device. The medium was exchanged to phosphate buffered saline (PBS, pH 7.4). No precipitation was found for over one year at 4°C.

The complexation of PtNP to HSA was conducted by adding HSA to the PtNP solution (PtNP/HSA = 1/1). Gel permeation chromatography (Sephadex G25) of the obtained protein displayed a single elution peak. Notably, TEM images demonstrated the formation of equivalent complex of HSA and PtNP (Figure 3A). Close inspections of TEM micrographs revealed that each PtNP is accommodated in the center of the protein (Figure 3B). One feasible binding mode is a covalent linkage of PtNP in the protein. While the catalase activity of HSA alone, the concentration of \(H_2O_2\) was not suppressed by HSA alone. For that reason, SOD activity of the albumin protein is excluded. The IC\(_{50}\) of HSA-PtNP complex is smaller than that of the best synthetic SOD model Mn(III)-tetrakis(N-methylpyridinium)porphyrin (Mn-TMPyP) [29] and resembled the value of native Cu,Zn-SOD [33]. We infer that the HSA-PtNP complex possesses a strong capability to catalyze the dismutation of \(O_2^-\) again.

Antioxidant activities of HSA–PtNP complex

The SOD activity of the HSA-PtNP complex was evaluated in phosphate buffered (PB) solution using the xanthine–(xanthine oxidase–)ferricytochrome \(c\) (Cyt. \(c\)) assay [27–29]. In the presence of the HSA-PtNP complex, the Cyt. \(c\) reduction by \(O_2^-\) was inhibited significantly. The IC\(_{50}\) value (the concentration of enzyme necessary to attain 50% inhibition of the Cyt. \(c\) reduction) of the HSA-PtNP complex was determined to be 0.16 \(\mu\)M (Table 1). Under our experimental conditions, the reduction of Cyt. \(c\) was not suppressed by HSA alone. For that reason, SOD activity of the albumin protein is excluded. The IC\(_{50}\) of HSA-PtNP complex is smaller than that of the best synthetic SOD model Mn(III)-tetrakis(N-methylpyridinium)porphyrin (Mn-TMPyP) [29] and resembled the value of native Cu,Zn-SOD [33]. We infer that the HSA-PtNP complex possesses a strong capability to catalyze the dismutation of \(O_2^-\) again.

Next, the catalase activity of the HSA-PtNP complex was examined by measuring the \(H_2O_2\) decomposition. In the presence of HSA-PtNP, the \(H_2O_2\) concentration declined considerably and reached zero after 180 min (Figure 4). The \(T_{50}\) value (time required for quenching half of \(H_2O_2\)) of HSA-PtNP was 19 min (Table 1). On the one hand, with the coexistence of HSA alone, the concentration of \(H_2O_2\) was not changed. These results imply that the catalase activity of HSA-PtNP complex was based on the PtNP in the protein. While the \(T_{50}\) value is at least two order of magnitude larger than that of native catalase, this platinated protein showed much higher \(H_2O_2\) dismutation activity than Mn-TMPyP [34]. Overall, we concluded that the HSA-PtNP complex shows strong abilities to catalyze the dismutation of both \(O_2^-\) and \(H_2O_2\).

### Table 3. \(O_2\) binding parameters of Hb-HSA\(_3\) and Hb-HSA\(_3\)(PtNP) clusters in PBS solution (pH 7.4) at 37°C.

| Hemoproteins          | \(P_{50}\) (Torr) | \(n\) | \(k_{\text{on}}\) (l·mol\(^{-1}\)·s\(^{-1}\)) |
|-----------------------|-------------------|-------|------------------------|
| Hb                    | 23                | 2.6   | 0.037                  |
| Hb-HSA\(_3\)          | 9                 | 1.5   | 0.035                  |
| Hb-HSA\(_3\)(PtNP)    | 9                 | 1.5   | 0.039                  |

doi:10.1371/journal.pone.0110541.t003

Figure 9. Time course of metHb level of Hb-HSA\(_3\) and Hb-HSA\(_3\)(PtNP) clusters. (Hb) = 10 \(\mu\)M in \(20 \mu\)M \(H_2O_2\) solution at 25°C. doi:10.1371/journal.pone.0110541.g009

Synthesis and structure of Hb-HSA\(_3\)(PtNP) cluster

The Hb-HSA\(_3\) cluster with the average Hb/HSA ratio of 3.0 was synthesized according to our previously reported procedure with some modifications (See Materials and Methods). Size exclusion chromatography (SEC) of the reaction mixture of SMCC-bound Hb and HSA exhibited new peaks of Hb-HSA\(_3\) heteropentamer (shoulder), Hb-HSA\(_3\) heterotetramer, and Hb-HSA\(_3\) heterotrimer (Figure 5); the major product was Hb-HSA\(_3\) (42%). By gel filtration chromatography (GFC), all the cluster fractions were harvested together (yield: 80% based on Hb). Unreacted free HSA was removed completely (Figure 5). The
average HSA/Hb ratio was determined to be 2.8–3.2 using Hb and total protein assays. This protein cluster is shown as Hb-HSA3. The CD spectral pattern and intensity of the Hb-HSA3 cluster agreed well with the sum of the Hb spectrum and a threefold-enlarged HSA spectrum (Figure 6). This observation also supports the average HSA/Hb as 3 (mol/mol).

Then the Hb-HSA3 solution was added slowly to the PBS solution of PtNP, yielding Hb-HSA3(PtNP) hybrid cluster (PtNP/Hb-HSA3 = 1/1). From titration measurements [26], the K value and binding number of PtNP with the exterior HSA unit were ascertained as 1.1×10^3 M⁻¹ and 1.1, which are equal to the data observed for free HSA. The affinity of PtNP with HSA moeity of the cluster is satisfactorily high. Even though, PtNP may transfer to other plasma proteins after intravenous administration. To avoid such intermolecular exchanging reaction in vivo, covalent attaching of PtNP to the HSA unit would be beneficial. The isoelectric point (pI: 5.1) of Hb-HSA3 was unaltered by PtNP incorporation. HSA has a high molecular surface net charge, thereby the pI value is known to shift slightly by ligand binding [35]. Thus, our result suggests that the PtNP is not adhered onto the HSA surface, but that it is embedded into the HSA shell.

O₂ affinity and O₂ complex stability

The visible absorption spectral patterns of the Hb-HSA3 cluster in PBS solution (pH 7.4) under N₂, O₂, and CO atmosphere (deoxygen, oxy, and carbonyl forms) were fundamentally the same as those of Hb-HSA3 tetramer and native Hb (Figure 7, Table 2) [20,36]. In contrast, the PBS solution of Hb-HSA3(PtNP) cluster exhibited strong absorbance over the entire visible range. It is ascribed to the superposing of the PtNP absorption onto the Hb-HSA3 spectrum. Nevertheless, the absorption maxima of the Hb-HSA3 and Hb-HSA3(PtNP) clusters showed good mutual agreement, indicating that PtNP caused no alternation of electronic states of the hemes in Hb (Table 2).

The P₅₀ (O₂-partial pressure where Hb is half-saturated with O₂) and cooperativity coefficient (Hill coefficient, n) of Hb-HSA3 cluster (Figure 8, Table 3) were identical to the values of isolated Hb-HSA3 tetramer [20]. Moderate O₂ affinity of Hb-HSA3 cluster than native Hb might be attributable to the fact that the Cys-93β residue in Hb was blocked by the crosslinking agent SMCC and that Lys-82β was exploited as a binding partner of Cys-34 of HSA [20]. Nonetheless, the high O₂ affinity might be favorable in application as a potential O₂ carrier. Winslow et al. demonstrated that HBOC with a low O₂ affinity engenders excessive O₂ release in the arterioles and thereby invokes excessive O₂ release in the arterioles and thereby invokes a weak antioxidant property. As described earlier in this report, CSA itself showed no measurable SOD or catalase activities in our experimental conditions with a large excess amount of O₂ and H₂O₂ (Table 1). Actually, HSA is known to be the predominant antioxidant in plasma (in vivo). Blache et al. estimated that 70% of the free-radical trapping activity of serum is attributed to HSA [41]. Otagiri et al. found that the antioxidant capabilities of HSA are attributable to the six methionine residues and Cys-34 [42]. Therefore, we inferred that covalent wrapping with HSAs stabilizes the core Hb structure and affords a weak antioxidant effect to the hemes in Hb.

Unexpectedly, the Kox value of Hb-HSA3(PtNP) cluster (0.039 h⁻¹) was almost identical to those observed for Hb-HSA3 and Hb. Kim et al. synthesized various protein-coated PtNPs and analyzed their ROS scavenging activities [24]. They demonstrated that O²⁻ and H₂O₂ dismutation activities of the protein-coated PtNPs are greatly affected by the physicochemical properties and interior shape of the protein shells. In the Hb-HSA3(PtNP) cluster, the PtNP is bound to the front side of Hb (Figure 2B), whereas the Cys-34 connection site to the Hb center is located on the front side of HSA. The accessibility of O²⁻ and H₂O₂ from the Hb to PtNP in the HSA shell might be restricted because no accessible channel exists in the proteins.

Finally, we investigated the O₂ complex stability of Hb-HSA3(PtNP) cluster in aqueous H₂O₂ solution. The H₂O₂ concentration in the human blood is assumed to be tens of micromolars (≈35 μM) [43]. Therefore, the oxidation rates of Hb-HSA3(PtNP), Hb-HSAβ, and Hb in aqueous 20 μM H₂O₂ solution were examined. The time courses of the absorbance increase at 630 nm (which is due to metHb formation) were markedly different in these protein solutions (Figure 9). Native Hb showed a biphasic autoxidation curve. Approximately 50% Hb is oxidized rapidly in the initial phase within 30 min, followed by a second slow oxidation process. The metHb formation level reached 72% after 180 min. It is accepted that the α subunits in Hb are oxidized easily with respect to the β subunits [13]. Because the heme concentration was 40 μM ([Hb] = 10 μM), the α subunit oxidation occurred first, and subsequently the β subunits were oxidized.

The rate of metHb formation, however, was somewhat low in the Hb-HSA3 cluster. In the initial phase, the metHb level increased to 37% within 30 min, followed by a slow oxidation reaction. This low rate appears to be attributable to a wrapping effect of HSA shell. As expected, the Hb-HSA3(PtNP) cluster was remarkably stable in H₂O₂ solution. We observed no initial oxidation process and only 17% metHb after 180 min, which is 24% of the value of native Hb. This result derives from the high antioxidant activity of the HSA-PtNP unit at the periphery. Actually the oxidation rate of Hb in the coexistence of HSA-PtNP and HSA (Hb/HSA-PtNP/HSA = 1/1/2), that are not covalently linked, was higher than that of the cluster. We can therefore conclude that the HSA-PtNP shell acts as an efficient scavenger for external H₂O₂ and achieves protection of the core Hb.
Conclusion

A citrate-reduced PtNP (d = 1.8 nm) binds strongly within a cleft of HSA, generating a stable HSA-PtNP complex. This platinated protein showed high O$_2$\(^{\ast}\) and H$_2$O$_2$ dissimutation activities. The Hb-HSA$_2$ cluster also captured PtNP into the external HSA unit. The obtained Hb-HSA$_2$-PtNP cluster formed an extremely stable O$_2$ complex even in H$_2$O$_2$ solution. These results suggest that the Hb-HSA$_2$-PtNP cluster with (i) negative surface net charges, (ii) high O$_2$ affinity, and (iii) antioxidant activities can be of tremendous medical importance as an alternative material to RBCs for transfusion in many clinical situations involving ischemia-reperfusion injury.

Author Contributions

Conceived and designed the experiments: HH TK. Performed the experiments: HH RH KY CB TK. Analyzed the data: HH RH KY CB TK. Contributed to the writing of the manuscript: CB TK.

References

1. Squires JE (2002) Artificial blood. Science 295: 1002–1008.
2. Pearce LB, Gavrilov MS, Rentko VT, Moon-Massat PF, Rausch GW (2006) HBOCs-201 (Hemoglobin Glutamater-250 (Bovine), Hemopare): clinical studies. In: Winslow RM, editor. Blood substitutes. San Diego: Elsevier: 437–450.
3. Jähn JS, Sadligh A, Doherty L, Li A, Kim HW (2011) Hemoglobin-based oxygen carriers: history, limits, brief summary of the state of the art, including clinical trials. In: Betti S, Mozzarelli A, editors. Chemistry and biochemistry of oxygen therapeutics: From transfusion to artificial blood. West Sussex: John Wiley & Sons: 301–316.
4. Kluger R, Lai FE (2013) HBOCs from chemical modification of Hb. In: Kim HW, Greenburg AG, editors. Hemoglobin-based oxygen carriers as red cell substitutes and oxygen oxygenators. Berlin Heidelberg: Springer-Verlag: 159–183.
5. Mondery-Pawlowski CL, Tian LL, Pan V, Gupta AS (2013) Synthesis approaches to RBC mimicry and oxygen oxygen carriers. Biomacromolecules 14: 939–948.
6. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM (2008) Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death. J Am Med Assoc 299: 2304–2312.
7. Kluger R (2010) Red cell substitutes from hemoglobin –Do we start all over again? Curr Opin Chem Biol 14: 538–543.
8. Shultz SC, Grady B, Cole F, Hamilton I, Burhop K, et al. (1993) A role of endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 122: 301–308.
9. Doherty DH, Doyle MP, Curry SR, Vali RJ, Fattor TJ, et al. (1998) Rate of binding and redox side reactions producing rhombic heme and heme degradations. J Biol Chem 273: 8067–8075.
10. Tsuruga M, Matsuoka M, Hachimori A, Sugawara Y, Shikama K (1998) The core-shell architecture of hemoglobin and human serum albumin as an artificial O$_2$ carrier. Biomacromolecules 14: 1816–1822.
11. Buehler PW, Boykins RA, Jia Y, Norris S, Freedberg DI, et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38–52.
12. Michel CC (1996) Transport of macromolecules through microvascular walls. In: Winslow RM, editor. Oxygen carrier. Biomacromolecules 14: 1816–1822.
13. Tsuruga M, Matsuoka M, Hachimori A, Sugawara Y, Shikama K (1998) The core-shell architecture of hemoglobin and human serum albumin as an artificial O$_2$ carrier. Biomacromolecules 14: 1816–1822.
14. Salin ML, McCord JM (1975) Free radicals and inflammation. J Clin Invest 56: 1139–1152.
15. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. Arch Biochem Biophys 222: 458–475.
16. D’Agnilloo F, Chang TMS (1998) Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat Biotechnol 16: 676–679.
17. Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML, et al. (1998) Arterial oxygenation of the naturally occurring human serum albumin-human serum albumin complex without hydroxyl radical formation. Chem Asian J 9: 83–86.
18. Suhr S, Mielckes H, Brick P, Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding site. Nat Struct Biol 5: 827–834.
19. Kato R, Akiyama M, Kawakami H, Komatsu T (2014) Superoxide dismutase activity of the naturally occurring human serum albumin-human serum albumin without hydroxyl radical formation. Chem Asian J 9: 83–86.
20. Curry S, Mielckes H, Brick P, Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding site. Nat Struct Biol 5: 827–834.
21. Bhattacharya AA, Curry S, Frank N (2000) Binding of the general anesthetics and halothane to human serum albumin. J Biol Chem 275: 38731–38738.
22. Ghuman J, Zunzain PA, Petipas I, Bhattacharya AA, Otagiri M, et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38–52.
23. Weser U, Schobutz LM (1981) Imidazole-bridged copper complexes as Cu$_2$Zn$_2$-superoxide dismutase models. J Mol Catal 13: 231–236.
24. San BH, Moh SH, Kim KK (2012) The effect of protein shells on the antioxidation activity of protein-encapsulated platinum nanoparticles. J Mater Chem 22: 1714–1719.
25. Bond GC (1956) The research of enzymology with deuterium over various types of platinum catalyst. Trans Faraday Soc 52: 1235–1244.
26. Cañaveras F, Madeureo R, Sevilla JM, Blázquez M, Pineda T (2012) Role of the functionalization of the gold nanoparticles surface on the formation of bioconjugates with human serum albumin. J Phys Chem C 116: 10430–10437.
27. Faulkner KM, Lieschew SI, Fridovich I (1994) Stable Mn(III) porphyrins mimics superoxide dismutase in vitro and substitute for in vivo. J Biol Chem 269: 23741–23746.
28. Ohno H, Shimazaki Y, Odani A, Yamashita O, Mori, et al. (2000) Synthesis and characterization of imidazole-bridged dinuclear complexes as active site models of Cu$_2$Zn$_2$-SOD. J Am Chem Soc 122: 5733–5741.
29. Hamasaki T, Kashiwagi T, Imada T, Nakamichi N, Aramaki S, et al. (2008) Kinetic Analysis of superoxide radical-scavenging and hydroxyl radical-scavenging activities of platinum nanoparticles. Langmuir 24: 7344–7349.
30. San BH, Moh SH, Kim KK (2012) The effect of protein shells on the antioxidation activity of protein-encapsulated platinum nanoparticles. J Mater Chem 22: 1714–1719.
31. Bhattacharya AA, Curry S, Frank N (2000) Binding of the general anesthetics and halothane to human serum albumin. J Biol Chem 275: 38731–38738.
32. Ghuman J, Zunzain PA, Petipas I, Bhattacharya AA, Otagiri M, et al. (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353: 38–52.
33. Weser U, Schobutz LM (1981) Imidazole-bridged copper complexes as Cu$_2$Zn$_2$-superoxide dismutase models. J Mol Catal 13: 231–236.